Skip to content

Clinical Observation on the Effectiveness of Tongqiao Sanjie Recipe with Ultrasonic Nebulized Nasal Inhalation in Treating OSAHS Caused by Adenoid Hypertrophy in Children

Clinical Observation on the Effectiveness of Tongqiao Sanjie Recipe with Ultrasonic Nebulized Nasal Inhalation in Treating OSAHS Caused by Adenoid Hypertrophy in Children

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004542
Enrollment
Unknown
Registered
2020-12-23
Start date
2021-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OSAHS caused by adenoid hypertrophy in children

Interventions

Sponsors

Tianshan Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: Western medical standards: 1. PSG monitoring meets the standards of the "Draft Guidelines for Childhood OSAHS Diagnosis and Treatment (Urumqi)" formulated by the Otolaryngology Branch of the Chinese Medical Association in 2007; 2. OSAHS children were born at full term, and their height and weight at birth were within the normal range There are no special circumstances in the feeding history and growth history; 3. The children with OSAHS in the group are between 3 and 12 years old, and have not yet entered puberty, and their living environment is not significantly different; 4. All children are identified as adenoids ( Pharyngeal tonsils) hypertrophy; 5. Mometasone furoate nasal spray was not used for 1 month before treatment. TCM standards: Refer to the "Thirteenth Five-Year Plan" textbooks for higher education in the Chinese medicine industry in the country, and the "Chinese Medicine Otorhinolaryngology" published by People's Medical Publishing House edited by Ruan Yan. Meet the "snoring disease" phlegm and blood stasis mutual accumulation standard.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed by PSG monitoring as central or mixed OSAHS; 2. The child has congenital and genetic diseases and craniofacial deformities; 3. Severe neonatal asphyxia, hypoxic ischemic encephalopathy at birth; 4. A history of chronic diseases such as tuberculosis, viral hepatitis, nephrotic syndrome or major trauma after birth; 5. Children who have had a history of cerebral palsy and seizures after birth; 6. Recurrent history of upper respiratory tract infection; 7. Simple or accompanied by tonsillar hypertrophy or higher or upper respiratory tract mouth, laryngopharyngeal part and other causes of airway stenosis or even collapse; 8. Allergic to research drugs.

Design outcomes

Primary

MeasureTime frame
AHI;LSaO2;

Countries

China

Contacts

Public ContactChen Jie

Tianshan Hospital of Traditional Chinese Medicine

13671636790@163.com+8613671636790

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026